U.S., Aug. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07745725) titled 'A Phase II Study of TollB-001 Tablets in Systemic Sclerosis' on July 28.
Brief Summary: The goal of this Phase II study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of TollB-001 Tablets in adults aged 18 to 70 years (male or female) with systemic sclerosis (SSc).
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Systemic Sclerosis (SSc)
Intervention:
DRUG: TollB-001 Tablet
TollB-001 Tablets
DRUG: Placebo
Placebo Tablets
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Toll Biotech Co. Ltd. (Beijing)
Published by HT Digital Content Services with permission from Health Daily Digest....